Jamil S. Sulieman, MD, FAASM
CONTACT US 808-234-0033
A new tool in the fight against sleep apnea
Tirzepatide 9Mounjaro · Zepbound)
sold under the brand names Mounjaro and Zepbound, is a medication that has shown remarkable results in clinical trials. It was originally developed to treat type 2 diabetes and obesity, but studies have confirmed: it also significantly improves obstructive sleep apnea.
​
The FDA has approved Zepbound specifically for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This makes it the first medicine treatment available for sleep apnea.
Navigating coverage — we do the hard part
Insurance coverage for Tirzepatide varies significantly by plan and requires a comprehensive documentation protocol. Many patients find the approval process confusing and time-consuming.
​
At The Sleep Lab, we specialize in helping patients establish eligibility, navigate their specific insurance plan's requirements, and document their usage and adherence, all of which are critical to being approved for coverage of these medications.